Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells

Hossein Aghamollaei | Mostafa Ghanei | Mohammad Javad Rasaee | Hamid Bakherad | Mahdi Fasihi-Ramandi | Seyed Latif Mousavi Gargari | Ali Mohammad Latifi | Ramezan Ali Taheri

---

URL :   http://research.shahed.ac.ir/WSR/WebPages/Report/PaperView.aspx?PaperID=158486
Date :  2021/04/12
Publish in :    Biotechnology and Applied Biochemistry
DOI :  https://doi.org/10.1002/bab.1916
Link :  http://dx.doi.org/10.1002/bab.1916
Keywords :glucose-regulated protein 78, Camelidae antibody, cancer detection, nanobody, unfold protein response

Abstract :

---

Glucose‐regulated protein 78 (GRP78) is an endoplasmic reticulum (ER) chaperone that has been shown that is overexpressed in cancer cells. Overexpression of GRP78 on cancer cells makes this molecule a suitable candidate for cancer detection and targeted therapy. VHH is the binding fragment of camelid heavy‐chain antibodies also known as “nanobody.” The aim of this study is to isolate and produce a new recombinant nanobody using phage display technique to detect cancer cells. Using the c‐terminal domain of GRP78 (CGRP) as an antigen, four rounds of biopanning were performed, and high‐affinity binders were selected by ELISA. Their affinity and functionality were characterized by surface plasmon resonance (SPR) cell ELISA and immunocytochemistry. A unique nanobody named V80 was purified. ELISA and SPR showed that this antibody had high specificity and affinity to the GRP78. Immunofluorescence analysis showed that V80 could specifically bind to the HepG2 and A549 cancer cell lines. This novel recombinant nanobody could bind to the cell surface of different cancer cells. After further evaluation, this nanobody can be used as a new tool for cancer detection and tumor therapy.